Detalles de la búsqueda
1.
Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.
J Med Virol
; 88(5): 798-806, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26412111
2.
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet
; 378(9787): 229-37, 2011 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21763935
3.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Lancet
; 378(9787): 238-46, 2011 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21763936
4.
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Antimicrob Agents Chemother
; 54(2): 718-27, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19933797
5.
Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Antivir Ther
; 14(1): 103-9, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19320243
6.
Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Nucleosides Nucleotides Nucleic Acids
; 25(1): 89-107, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16440988
7.
Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Antivir Ther
; 19(8): 819-23, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24704709
8.
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
AIDS Patient Care STDS
; 28(4): 168-75, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24660840
9.
Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
Antivir Ther
; 18(2): 253-6, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22951490
10.
Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
AIDS
; 27(6): 889-897, 2013 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-23276806
11.
96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
Antivir Ther
; 18(8): 967-77, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23714781
12.
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.
AIDS
; 27(6): 939-950, 2013 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-23211772
13.
The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.
J Acquir Immune Defic Syndr
; 59(1): 47-54, 2012 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21997204
14.
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
J Acquir Immune Defic Syndr
; 59(1): 39-46, 2012 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22067667
15.
Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.
AIDS Res Hum Retroviruses
; 28(5): 437-46, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21902621
16.
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
J Acquir Immune Defic Syndr
; 60(1): 33-42, 2012 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22343174
17.
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.
AIDS
; 24(1): 55-65, 2010 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-19926964
18.
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.
AIDS Res Hum Retroviruses
; 26(6): 621-4, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20507207
19.
Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
Antimicrob Agents Chemother
; 47(6): 1842-52, 2003 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12760857
20.